LAWRENCEKWONGLAWRENCE KWONG9792KWONG, LAWRENCEAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25538079Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KCScience signalingSystematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014 12 23; 7(357):ra121.Sci Signal2014-12-23T00:00:002014Systematic identification of signaling pathways with potential to confer anticancer drug resistance.1515 Holcombe Blvd.Houston77030TXAuthorship 1841028Authorship 19042916Authorship 19324818Authorship 193717122750848Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin LCancer discoverymicroRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-? signaling in glioblastoma. Cancer Discov. 2012 Aug; 2(8):736-49.Cancer Discov2012-06-29T00:00:002012microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-? signaling in glioblastoma.24327696Kwong LN, Heffernan TP, Chin LCancer discoveryA systems biology approach to personalizing therapeutic combinations. Cancer Discov. 2013 Dec; 3(12):1339-44.Cancer Discov2013-12-01T00:00:002013A systems biology approach to personalizing therapeutic combinations.GI Medical OncologyInvestigational Cancer TherapeuticsLeukemiaMelanoma Medical OncologySurgical OncologySystems BiologyTranslational Molecular PathologyMD AndersonJEFFREY EGERSHENWALDJEFFREY E GERSHENWALD8667GERSHENWALD, JEFFREY EProfessorJENNIFERWARGOJENNIFER WARGO9904WARGO, JENNIFERAssociate ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorJEAN NICOLASVAUTHEYJEAN NICOLAS VAUTHEY8766VAUTHEY, JEAN NICOLASProfessorFUNDAMERIC-BERNSTAMFUNDA MERIC-BERNSTAM8778MERIC-BERNSTAM, FUNDAProfessorALEXANDERLAZARALEXANDER LAZAR9206LAZAR, ALEXANDERProfessorMICHAEL ADAVIESMICHAEL A DAVIES8753DAVIES, MICHAEL AAssociate ProfessorMILINDJAVLEMILIND JAVLE9389JAVLE, MILINDProfessor3.819540.00998237351research areas1.260780.027953175coauthor of86.032819.035660similar to1186selected publicationsAuthorship 2238122Authorship 2262441Authorship 2290143Authorship 2292211Authorship 234142117360473Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, Haag JD, Chen KS, Waller JL, Gould MN, Dove WFProceedings of the National Academy of Sciences of the United States of AmericaA target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proc Natl Acad Sci U S A. 2007 Mar 06; 104(10):4036-41.Proc Natl Acad Sci U S A2007-02-27T00:00:002007A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer.19111873Kwong LN, Chin LCancer cellThe metastasis problem gets stickier. Cancer Cell. 2009 Jan 06; 15(1):1-2.Cancer Cell2009-01-06T00:00:002009The metastasis problem gets stickier.20141832Kwong LN, Chin LCellThe brothers RAF. Cell. 2010 Jan 22; 140(2):180-2.Cell2010-01-22T00:00:002010The brothers RAF.21091817Chen M, Lee G, Kwong LN, Lamont S, Chaves CJournal of neuroimaging : official journal of the American Society of NeuroimagingCerebral white matter lesions in patients with Crohn's disease. J Neuroimaging. 2012 Jan; 22(1):38-41.J Neuroimaging2010-11-17T00:00:002010Cerebral white matter lesions in patients with Crohn's disease.24453001Kwong LN, Chin LCancer researchChromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions. Cancer Res. 2014 Mar 15; 74(6):1814-21.Cancer Res2014-01-22T00:00:002014Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions.Authorship 2498781Authorship 2554852Authorship 2555471Authorship 260875117435219Kwong LN, Shedlovsky A, Biehl BS, Clipson L, Pasch CA, Dove WFGeneticsIdentification of Mom7, a novel modifier of Apc(Min/+) on mouse chromosome 18. Genetics. 2007 Jun; 176(2):1237-44.Genetics2007-04-15T00:00:002007Identification of Mom7, a novel modifier of Apc(Min/+) on mouse chromosome 18.19928355Kwong LN, Dove WFAdvances in experimental medicine and biologyAPC and its modifiers in colon cancer. Adv Exp Med Biol. 2009; 656:85-106.Adv Exp Med Biol2009-01-01T00:00:002009APC and its modifiers in colon cancer.20574449Heyer J, Kwong LN, Lowe SW, Chin LNature reviews. CancerNon-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer. 2010 Jul; 10(7):470-80.Nat Rev Cancer2010-07-01T00:00:002010Non-germline genetically engineered mouse models for translational cancer research.24089444Kwong LN, Davies MAClinical cancer research : an official journal of the American Association for Cancer ResearchNavigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res. 2013 Oct 01; 19(19):5310-9.Clin Cancer Res2013-10-01T00:00:002013Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.Authorship 270945122983396Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin LNature medicineOncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012 Oct; 18(10):1503-10.Nat Med2012-09-16T00:00:002012Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.Authorship 273516118159898Kwong L, Chin L, Wagner SNAdvances in dermatologyGrowth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol. 2007; 23:99-129.Adv Dermatol2007-01-01T00:00:002007Growth factors and oncogenes as targets in melanoma: lost in translation?Authorship 2907499Authorship 2945151Authorship 2992873Authorship 3031457Authorship 3047091824983357Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJPloS oneClinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.PLoS One2014-07-01T00:00:002014Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.25705882Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin LThe Journal of clinical investigationCo-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70.J Clin Invest2015-02-23T00:00:002015Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.26153864Muller F, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee M, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RANatureCorrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2015 Sep 10; 525(7568):278.Nature2015-07-08T00:00:002015Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer.26450788Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin LCancer discoveryDual Roles of RNF2 in Melanoma Progression. Cancer Discov. 2015 Dec; 5(12):1314-27.Cancer Discov2015-10-08T00:00:002015Dual Roles of RNF2 in Melanoma Progression.26787600Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LNScientific reportsSomatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep. 2016 Jan 20; 6:19649.Sci Rep2016-01-20T00:00:002016Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.74Professor10Assistant Professor14Associate Professor26645196Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Liz?e G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu PCancer discoveryLoss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.Cancer Discov2015-12-08T00:00:002015Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.20520718Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN, Brennan C, Chin LPloS oneIntegrative genome comparison of primary and metastatic melanomas. PLoS One. 2010 May 24; 5(5):e10770.PLoS One2010-05-24T00:00:002010Integrative genome comparison of primary and metastatic melanomas.Authorship 841195Authorship 842049Authorship 846031Authorship 849734Authorship 850818Authorship 853036Authorship 853679Authorship 854090Authorship 854128Authorship 855108Authorship 859044Authorship 860693Authorship 86757328297679Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LNCell reportsIntegrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017 03 14; 18(11):2780-2794.Cell Rep2017-03-14T00:00:002017Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.PLoS OneClinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 9.Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimeticsClinical Cancer ResearchMAPK pathway inhibitors sensitize BRAF-mutant melanoma to an antibody-drug conjugate targeting GPNMB. Clinical Cancer Research. 22:6088-6098.MAPK pathway inhibitors sensitize BRAF-mutant melanoma to an antibody-drug conjugate targeting GPNMBNature MedicineErratum. Nature Medicine. 18:1857.ErratumCurrent Treatment Options in OncologyGenomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Current Treatment Options in Oncology. 17.Genomic Profiling of Biliary Tract Cancers and Implications for Clinical PracticeCancer DiscoveryDual roles of RNF2 in melanoma progression. Cancer Discovery. 5:1314-1327.Dual roles of RNF2 in melanoma progressionCell ReportsOncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Reports. 15:2012-2024.Oncogenic BRAF-Mediated Melanoma Cell InvasionOncogeneTargeted therapy for melanoma. Oncogene. 33:1-9.Targeted therapy for melanomaOncotargetEfficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 7:39595-39608.Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer modelsNatureErratum. Nature. 525:278.ErratumCancer DiscoveryCancer Discovery. 6:202-216.Cancer DiscoveryCancer DiscoveryAnalysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockadeScientific ReportsSomatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Scientific Reports. 6.Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene ExpressionHepatologyLoss of the transforming growth factor-β effector β2-Spectrin promotes genomic instability. Hepatology. 65:678-693.Loss of the transforming growth factor-β effector β2-Spectrin promotes genomic instability22895339Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RANaturePassenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012 Aug 16; 488(7411):337-42.Nature2012-08-16T00:00:002012Passenger deletions generate therapeutic vulnerabilities in cancer.28658632Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LNCell reportsIntegrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017 06 27; 19(13):2878-2880.Cell Rep2017-06-27T00:00:002017Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.Authorship 88721911Authorship 88788344Authorship 88839444Authorship 88867830D009857Genes & Molecular Sequences3576730.75836OncogenesD048493Chemicals & Drugs32012770.583873Proto-Oncogene Proteins B-rafD001650Disorders1744860.682476Bile Duct NeoplasmsAuthorship 90711911Authorship 9113772Authorship 9123212Authorship 9124664Authorship 91278932Authorship 91302512Authorship 91335419Authorship 9143402Authorship 9151723Authorship 91535821Authorship 9175191Authorship 9204772Authorship 92144717Authorship 92171924Authorship 9225546Authorship 9267233Authorship 92803012Authorship 92818934Authorship 92843230Authorship 9303292Authorship 93164011Authorship 9366851227167191Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz SOncotargetEfficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 2016 Jun 28; 7(26):39595-39608.Oncotarget2016-06-28T00:00:002016Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.27301722Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JACancer discoveryAnalysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.Cancer Discov2016-06-14T00:00:002016Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.27515299Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PMClinical cancer research : an official journal of the American Association for Cancer ResearchMAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clin Cancer Res. 2016 Dec 15; 22(24):6088-6098.Clin Cancer Res2016-08-11T00:00:002016MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.27210749Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo WCell reportsOncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep. 2016 05 31; 15(9):2012-24.Cell Rep2016-05-19T00:00:002016Oncogenic BRAF-Mediated Melanoma Cell Invasion.27658789Jain A, Kwong LN, Javle MCurrent treatment options in oncologyGenomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol. 2016 11; 17(11):58.Curr Treat Options Oncol2016-11-01T00:00:002016Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.28078106Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZJournal of gastrointestinal oncologyAdvances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827.J Gastrointest Oncol2016-12-01T00:00:002016Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.28114741Chen J, Shukla V, Farci P, Andricovich J, Jogunoori W, Kwong LN, Katz LH, Shetty K, Rashid A, Su X, White J, Li L, Wang AY, Blechacz B, Raju GS, Davila M, Nguyen BN, Stroehlein JR, Chen J, Kim SS, Levin H, Machida K, Tsukamoto H, Michaely P, Tzatsos A, Mishra B, Amdur R, Mishra LHepatology (Baltimore, Md.)Loss of the transforming growth factor-? effector ?2-Spectrin promotes genomic instability. Hepatology. 2017 02; 65(2):678-693.Hepatology2016-12-24T00:00:002016Loss of the transforming growth factor-? effector ?2-Spectrin promotes genomic instability.28178232Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin LNatureSynthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366.Nature2017-02-08T00:00:002017Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.28289141Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, Wang YA, Kwong LN, DePinho RAGenes & developmentOncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev. 2017 02 15; 31(4):370-382.Genes Dev2017-02-15T00:00:002017Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.28445987Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno LOncotargetContext-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 2017 Apr 11; 8(15):25395-25417.Oncotarget2017-04-11T00:00:002017Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.28514651Kwong LN, Zou L, Chagani S, Pedamallu CS, Liu M, Jiang S, Protopopov A, Zhang J, Getz G, Chin LCell reportsModeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Rep. 2017 05 16; 19(7):1304-1312.Cell Rep2017-05-16T00:00:002017Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma.28957718Yun C, Dashwood WM, Kwong LN, Gao S, Yin T, Ling Q, Singh R, Dashwood RH, Hu MJournal of pharmaceutical and biomedical analysisAccurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS. J Pharm Biomed Anal. 2018 Jan 30; 148:42-50.J Pharm Biomed Anal2017-07-25T00:00:002017Accurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS.29112174Romano G, Kwong LNInternational journal of molecular sciencesmiRNAs, Melanoma and Microenvironment: An Intricate Network. Int J Mol Sci. 2017 Nov 07; 18(11).Int J Mol Sci2017-11-07T00:00:002017miRNAs, Melanoma and Microenvironment: An Intricate Network.29625050Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz NCellOncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 04 05; 173(2):321-337.e10.Cell2018-04-05T00:00:002018Oncogenic Signaling Pathways in The Cancer Genome Atlas.29463860Romano G, Chagani S, Kwong LNOncogeneThe path to metastatic mouse models of colorectal cancer. Oncogene. 2018 05; 37(19):2481-2489.Oncogene2018-02-21T00:00:002018The path to metastatic mouse models of colorectal cancer.29496664Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AECancer discoveryIn Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 05; 8(5):568-581.Cancer Discov2018-03-01T00:00:002018In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.29496665Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LNCancer discoveryA Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.Cancer Discov2018-03-01T00:00:002018A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.29409809Reicher A, Fo?elteder J, Kwong LN, Pichler MCancer lettersCrosstalk between the Notch signaling pathway and long non-coding RNAs. Cancer Lett. 2018 04 28; 420:91-96.Cancer Lett2018-02-02T00:00:002018Crosstalk between the Notch signaling pathway and long non-coding RNAs.29563139Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JWClinical cancer research : an official journal of the American Association for Cancer ResearchInduction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 10 01; 24(19):4771-4784.Clin Cancer Res2018-03-21T00:00:002018Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.30268436Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani RCell systemsA Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-? Superfamily. Cell Syst. 2018 10 24; 7(4):422-437.e7.Cell Syst2018-09-26T00:00:002018A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-? Superfamily.30181170Romano G, Kwong LNCancer discoveryBRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas. Cancer Discov. 2018 09; 8(9):1064-1065.Cancer Discov2018-09-01T00:00:002018BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.30510016Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AECancer discoveryCorrection: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 Dec; 8(12):1654.Cancer Discov2018-12-01T00:00:002018Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.D018281Disorders1604750.680576CholangiocarcinomaD008545Disorders68053010.290068MelanomaPathologyAuthorship 943676229270700Romano G, Kwong LNCancer metastasis reviewsDiagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer Metastasis Rev. 2018 03; 37(1):45-53.Cancer Metastasis Rev2018-03-01T00:00:002018Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy.Authorship 946785131058252Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JEJCO precision oncologyBiological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol. 2018; 2018.JCO Precis Oncol2018-06-14T00:00:002018Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.Authorship 9531851331375515Aloia A, M?llhaupt D, Chabbert CD, Eberhart T, Fl?ckiger-Mangual S, Vukolic A, Eichhoff O, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJClinical cancer research : an official journal of the American Association for Cancer ResearchA Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res. 2019 11 15; 25(22):6852-6867.Clin Cancer Res2019-08-02T00:00:002019A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors.Authorship 953411431386048Santos-Pinheiro F, Park M, Liu D, Kwong LN, Cruz S, Levine NB, O'Brien BJ, Chen MNeuro-oncology practiceSeizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas. Neurooncol Pract. 2019 May; 6(3):209-217.Neurooncol Pract2018-07-09T00:00:002018Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas.Authorship 978478232096245Zhu Y, Kwong LNHepatology (Baltimore, Md.)Insights Into the Origin of Intrahepatic Cholangiocarcinoma From Mouse Models. Hepatology. 2020 07; 72(1):305-314.Hepatology2020-07-01T00:00:002020Insights Into the Origin of Intrahepatic Cholangiocarcinoma From Mouse Models.Authorship 986581732252259Reicher A, Harris AL, Prinz F, Kiesslich T, Wei M, ?llinger R, Rad R, Pichler M, Kwong LNInternational journal of molecular sciencesGeneration of An Endogenous FGFR2-BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells. Int J Mol Sci. 2020 Apr 02; 21(7).Int J Mol Sci2020-04-02T00:00:002020Generation of An Endogenous FGFR2-BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells.Authorship 996053232747369Koleilat MK, Kwong LNCancer discoverySame Name, Different Game: EGFR Drives Intrinsic KRASG12C Inhibitor Resistance in Colorectal Cancer. Cancer Discov. 2020 08; 10(8):1094-1096.Cancer Discov2020-08-01T00:00:002020Same Name, Different Game: EGFR Drives Intrinsic KRASG12C Inhibitor Resistance in Colorectal Cancer.Authorship 9995211332923885Cao J, Hu J, Liu S, Meric-Bernstam F, Abdel-Wahab R, Xu J, Li Q, Yan M, Feng Y, Lin J, Zhao S, Wang J, Kwong LN, Hu J, Carapeto F, Borad MJ, Wang K, Javle M, Zhao HJCO precision oncologyIntrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precis Oncol. 2020; 4.JCO Precis Oncol2020-06-01T00:00:002020Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients.Authorship 10070201033328484Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle MScientific reportsGenomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 12 16; 10(1):22087.Sci Rep2020-12-16T00:00:002020Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.Authorship 1017159633907234Cheng LY, Haydu LE, Song P, Nie J, Tetzlaff MT, Kwong LN, Gershenwald JE, Davies MA, Zhang DYScientific reportsHigh sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci Rep. 2021 04 27; 11(1):9043.Sci Rep2021-04-27T00:00:002021High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.Authorship 1017687233947718Chagani S, Kwong LNCancer discoveryCholangiocarcinoma Risk Factors Open the Floodgates for Gut Microbes and Immunosuppressive Myeloid Cells. Cancer Discov. 2021 05; 11(5):1014-1015.Cancer Discov2021-05-01T00:00:002021Cholangiocarcinoma Risk Factors Open the Floodgates for Gut Microbes and Immunosuppressive Myeloid Cells.Authorship 1020795334111531Kawaguchi Y, Kopetz S, Kwong L, Xiao L, Morris JS, Tran Cao HS, Tzeng CD, Chun YS, Lee JE, Vauthey JNJournal of the American College of SurgeonsGenomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal?Cancer. J Am Coll Surg. 2021 08; 233(2):272-284.e13.J Am Coll Surg2021-06-07T00:00:002021Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal?Cancer.Authorship 1026143434304249Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, Lu Y, Mills GB, Field J, Villanueva J, Xu X, Herlyn M, Guo WOncogeneTargeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. 2021 09; 40(37):5590-5599.Oncogene2021-07-24T00:00:002021Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Authorship 10287884134462276Liu J, Rebecca VW, Kossenkov AV, Connelly T, Liu Q, Gutierrez A, Xiao M, Li L, Zhang G, Samarkina A, Zayasbazan D, Zhang J, Cheng C, Wei Z, Alicea GM, Fukunaga-Kalabis M, Krepler C, Aza-Blanc P, Yang CC, Delvadia B, Tong C, Huang Y, Delvadia M, Morias AS, Sproesser K, Brafford P, Wang JX, Beqiri M, Somasundaram R, Vultur A, Hristova DM, Wu LW, Lu Y, Mills GB, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Amaravadi RK, Kwong LN, Frederick DT, Boland GM, Salvino JM, Speicher DW, Flaherty KT, Ronai ZA, Herlyn MCancer researchNeural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Res. 2021 10 15; 81(20):5230-5241.Cancer Res2021-08-30T00:00:002021Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance.Authorship 1029191634482832Thirunavukarasu D, Cheng LY, Song P, Chen SX, Borad MJ, Kwong L, James P, Turner DJ, Zhang DYGenome biologyOncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. Genome Biol. 2021 09 06; 22(1):227.Genome Biol2021-09-06T00:00:002021Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection.Authorship 10295831234510503Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LNHepatology (Baltimore, Md.)The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308.Hepatology2021-12-06T00:00:002021The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.Authorship 10318691134675197Dai P, Wu LR, Chen SX, Wang MX, Cheng LY, Zhang JX, Hao P, Yao W, Zarka J, Issa GC, Kwong L, Zhang DYNature communicationsCalibration-free NGS quantitation of mutations below 0.01% VAF. Nat Commun. 2021 10 21; 12(1):6123.Nat Commun2021-10-21T00:00:002021Calibration-free NGS quantitation of mutations below 0.01% VAF.Authorship 10379892Authorship 10392216Authorship 10406131635102279Song P, Wu LR, Yan YH, Zhang JX, Chu T, Kwong LN, Patel AA, Zhang DYNature biomedical engineeringLimitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng. 2022 03; 6(3):232-245.Nat Biomed Eng2022-01-31T00:00:002022Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics.35171660Lapin M, Huang HJ, Chagani S, Javle M, Shroff RT, Pant S, Gouda MA, Raina A, Madwani K, Holley VR, Call SG, Dustin DJ, Lanman RB, Meric-Bernstam F, Raymond VM, Kwong LN, Janku FJCO precision oncologyMonitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol. 2022 02; 6:e2100197.JCO Precis Oncol2022-02-01T00:00:002022Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors.35257150Zhu Y, Kwong LNCancer discoveryIDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma. Cancer Discov. 2022 03 01; 12(3):604-605.Cancer Discov2022-03-01T00:00:002022IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma.Authorship 1043877835418222Zhang K, Song P, Dai P, Zhang JX, Wu LR, Cheng LY, Pinto A, Kwong L, Cabrera K, Wen R, Zhang DYACS sensorsCost-Efficient Sequence-Based Nonextensible Oligonucleotide in Real-Time PCR and High-Throughput Sequencing. ACS Sens. 2022 04 22; 7(4):1165-1174.ACS Sens2022-04-13T00:00:002022Cost-Efficient Sequence-Based Nonextensible Oligonucleotide in Real-Time PCR and High-Throughput Sequencing.35913398Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz SCancer researchTargeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6. Cancer Res. 2022 Sep 16; 82(18):3335-3344.Cancer Res2022-09-16T00:00:002022Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Authorship 10628587Authorship 10644131436820825Romano G, Paradiso F, Li P, Shukla P, Barger LN, El Naggar O, Miller JP, Liang RJ, Helms TL, Lazar AJ, Wargo JA, Taraballi F, Costello JC, Kwong LNCancer immunology researchMicroparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.Cancer Immunol Res2023-05-03T00:00:002023Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma.Authorship 10653441636871660Chagani S, De Macedo MP, Carapeto F, Wang F, Marzese DM, Wani K, Haydu LE, Peng W, Ong GT, Warren SE, Beechem JM, Hoon DSB, Mills GB, Tetzlaff MT, Lazar AJ, Kwong LN, Davies MAThe Journal of investigative dermatologyMultiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma. J Invest Dermatol. 2023 09; 143(9):1779-1787.e1.J Invest Dermatol2023-03-04T00:00:002023Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma.Authorship 10813871337821462Zhang DY, Zhu Y, Wu Q, Ma S, Ma Y, Shen ZC, Wang Z, Sun W, Zhou YC, Wang D, Zhou S, Liu Z, Kwong LN, Lu ZCell death & diseaseUSP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation. Cell Death Dis. 2023 10 11; 14(10):669.Cell Death Dis2023-10-11T00:00:002023USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation.Authorship 10836211437972659DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam FJournal of hepatologyConvergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb; 80(2):322-334.J Hepatol2023-11-14T00:00:002023Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.Authorship 10851203238060314Zhu Y, Zhang D, Shukla P, Jung YH, Malgulwar PB, Chagani S, Colic M, Benjamin S, Copland JA, Tan L, Lorenzi PL, Javle M, Huse JT, Roszik J, Hart T, Kwong LNJCI insightCRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight. 2024 Jan 23; 9(2).JCI Insight2024-01-23T00:00:002024CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessor